NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Insperity, Inc. ("Insperity" or the "Company") (NYSE:NSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Insperity and certain of its officers and/or directors […]
NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of CTO Realty Growth, Inc. ("CTO" or the "Company") (NYSE:CTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether CTO and certain of its officers
NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Dow Inc. ("Dow" or the "Company") (NYSE:DOW). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Dow and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company")(NASDAQ:RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to
NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Neogen Corporation ("Neogen" or the "Company") (NASDAQ:NEOG). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Neogen and certain of its officers and/or directors
NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Capricor and certain of its officers and/or
NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against XPLR Infrastructure, LP ("XPLR" or the "Company") (NYSE:XIFR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
NEW YORK CITY, NY / ACCESS Newswire / August 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are
TheDeepfake AI Market presents compelling growth opportunities, especially in regions like North America where technological maturity and regulatory evolution coexist. While drivers such as generative AI advancements and personalized content demand fuel adoption, market entry strategies must address risks like misinformation and legal ambiguity. B2B players should focus on ethical use cases, invest in detection
According to a new research report from The Insight Partners, the global hydrolyzed collagen market is observing significant growth owing to the wide application scope and strategic initiatives by key market players. https://mma.prnewswire.com/media/1586348/5449703/The_Insight_Partners_Logo.jpg The hydrolyzed collagen market value is expected to reach US$1.91 billion by 2031 from US$1.32 billion in 2024; it is expected to